Revolution Medicines (RVMD) Stock Price, News & Analysis

Company Overview

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations. These candidates are being evaluated in various phases of clinical development across solid tumors, with the goal of delivering first-in-class or best-in-class therapies for patients with limited treatment options.

Founded in 2015 and headquartered in Redwood City, California, Revolution Medicines operates research facilities in North America and collaborates with academic institutions and industry partners to accelerate innovation. The management team comprises experienced executives with deep expertise in oncology drug discovery, guiding the company’s strategic partnerships and clinical advancement efforts.

Key Stats

• Today's Range: $142.08 to $149.79
• 50-Day Range: $92.51 to $152.54
• 52-Week Range: $34.00 to $155.70
• Volume: 2.47 million shs
• Average Volume: 4.66 million shs
• Market Capitalization: $30.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $103.88
• Consensus Rating: Buy

Revolution Medicines Stock Analysis - MarketRank™

Revolution Medicines scored higher than 50% of companies evaluated by MarketBeat, and ranked 473rd out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Revolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 4 strong buy ratings, 16 buy ratings, no hold ratings, and 1 sell rating.

Downside Risk

Revolution Medicines has a consensus price target of $102.18, representing about 28.3% downside from its current price of $142.51.

Amount of Analyst Coverage

Revolution Medicines has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Revolution Medicines are expected to grow in the coming year, from ($7.42) to ($4.93) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revolution Medicines is -20.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revolution Medicines is -20.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Revolution Medicines has a P/B Ratio of 16.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.36% of the float of Revolution Medicines has been sold short.

Short Interest Ratio / Days to Cover

Revolution Medicines has a short interest ratio ("days to cover") of 3.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Revolution Medicines has recently decreased by 13.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Revolution Medicines does not currently pay a dividend.

Dividend Growth

Revolution Medicines does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.35

News Sentiment

Revolution Medicines has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Revolution Medicines this week, compared to 7 articles on an average week.

Search Interest

38 people have searched for RVMD on MarketBeat in the last 30 days. This is an increase of 322% compared to the previous 30 days.

MarketBeat Follows

26 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 767% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,499,532.00 in company stock.

Percentage Held by Insiders

8.20% of the stock of Revolution Medicines is held by insiders.

Percentage Held by Institutions

94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RVMD Stock Analysis - Frequently Asked Questions

How have RVMD shares performed this year?

Revolution Medicines' stock was trading at $79.65 at the start of the year. Since then, RVMD shares have increased by 78.9% and is now trading at $142.51.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) released its quarterly earnings data on Wednesday, May, 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by $0.46.
Read the conference call transcript.

When did Revolution Medicines IPO?

Revolution Medicines (RVMD) raised $231 million in an initial public offering (IPO) on Thursday, February 13th 2020. The company issued 14,000,000 shares at a price of $16.00-$17.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' top institutional shareholders include Dimensional Fund Advisors LP (0.40%), Bank of New York Mellon Corp (0.30%), Candriam S.C.A. (0.27%) and Pictet Asset Management Holding SA (0.28%). Insiders that own company stock include Thilo Schroeder, Stephen Michael Kelsey, Mark A Goldsmith, Margaret A Horn, Jack Anders, Xiaolin Wang, Lin Wei, Jeff Cislini, Sushil Patel and Barbara Weber.
View institutional ownership trends.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RVMD
• CIK: 1628171
• Web: www.revmed.com
• Phone: 650-481-6801
• Fax: N/A
• Employees: 250
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Revolution Medicines: $102.18
• High Price Target: $205.00
• Low Price Target: $70.00
• Potential Upside/Downside: -28.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.13 billion
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -80.79%
• Return on Assets: -58.49%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 7.14
• Quick Ratio: 7.14

Sales & Book Value

• Annual Sales: $11.58 million
• Price / Sales: 2,616.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.44 per share
• Price / Book: 16.89

Miscellaneous

• Outstanding Shares: 212,590,000
• Free Float: 195,160,000
• Market Cap: $30.30 billion
• Optionable: Optionable
• Beta: 1.41